• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT1

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2022 Sep 23;9(10):ofac493.
doi: 10.1093/ofid/ofac493. eCollection 2022 Oct.
Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication


Naoki Tani[SUP] 1 [/SUP], Hideyuki Ikematsu[SUP] 2 [/SUP], Takeyuki Goto[SUP] 1 [/SUP], Kei Gondo[SUP] 3 [/SUP], Takeru Inoue[SUP] 1 [/SUP], Yuki Yanagihara[SUP] 4 [/SUP], Yasuo Kurata[SUP] 4 [/SUP], Ryo Oishi[SUP] 5 [/SUP], Junya Minami[SUP] 5 [/SUP], Kyoko Onozawa[SUP] 5 [/SUP], Sukehisa Nagano[SUP] 6 [/SUP], Hiroyuki Kuwano[SUP] 7 [/SUP], Koichi Akashi[SUP] 1 [/SUP], Nobuyuki Shimono[SUP] 8 [/SUP], Yong Chong[SUP] 1 [/SUP]



Affiliations

Abstract

Background: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use.
Methods: This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 2-dose primary series. Spike-specific immunoglobulin G (IgG) titers were measured for SARS-CoV-2-naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and self-medicated antipyretics were reported daily for 7 days following vaccination through a web-based self-reporting diary.
Results: The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (β = .305, P < .001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk, 3.97 [95% confidence interval, 2.48-6.35]); however, the IgG titers after the booster dose were not associated with the presence or degree of fever after the second dose. There were no significant differences in the IgG titers by the use, type, or dosage of antipyretic medication.
Conclusions: These results suggest an independent correlation between mRNA vaccine-induced specific IgG levels and post-booster vaccination fever, without any significant influence of fever after the primary series. Antipyretic medications for adverse reactions should not interfere with the elevation of specific IgG titers.

Keywords: SARS-CoV-2; antibody; antipyretic; reactogenicity; vaccine.
 
Back
Top Bottom